Particle.news

Isomorphic Labs Raises $5 Billion to Scale Its AI Drug Platform

The round funds model development, pipeline expansion, global AI lab buildout to push first human trials by the end of the year.

Overview

  • Isomorphic Labs completed a $5 billion C round on Tuesday, November 17, 2026, co-led by Greenoaks and Sequoia with new investor a16z and continuing participation from Alphabet and prior backers.
  • The company says it will use the cash to speed development of its IsoDDE foundational simulation models, expand in-house and partner drug candidate pipelines, and build a global AI-driven bioengineering and translational infrastructure.
  • Isomorphic reports positive preclinical results in oncology and immunology and is preparing for first-in-human trials, targeting clinical entry by the end of 2026.
  • With this round, publicly disclosed funding for Isomorphic totals about $7.7 billion, and media reports had earlier linked the deal talks to roughly a $50 billion valuation, a negotiation the company has not described as closed prior to today’s announcement.
  • The raise highlights a wider AI-for-science trend of concentrated, large bets on a few platform leaders and sets up a test: clinical data and the cost of building automated labs and compute will determine whether these high valuations hold and how quickly new medicines reach patients.